Sarcopenic Obesity Is a Risk Factor for Worse Oncological Long-Term Outcome in Locally Advanced Rectal Cancer Patients: A Retrospective Single-Center Cohort Study.
body composition
locally advanced rectal cancer
morbidity
oncological long-term outcome
sarcopenia
sarcopenic obesity
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
05 Jun 2023
05 Jun 2023
Historique:
received:
09
05
2023
revised:
30
05
2023
accepted:
02
06
2023
medline:
12
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Malnutrition and skeletal muscle waste (sarcopenia) are known as predictive factors for a poor postoperative outcome. Paradoxically, obesity seems to be associated with a survival advantage in wasting diseases such as cancer. Thus, the interpretation of body composition indices and their impact on rectal cancer therapy has become more and more complex. The aim of this study was to evaluate body composition indices in locally advanced rectal cancer patients prior to therapy and their impact on short- and long-term outcomes. Between 2008 and 2018, 96 patients were included in this study. Pre-therapeutic CT scans were used to evaluate visceral and subcutaneous fat mass, as well as muscle mass. Body composition indices were compared to body mass index, morbidity, anastomotic leakage rate, local recurrency rate, and oncological long-term outcomes. Increased visceral fat ( Muscle waste, older age, and comorbidities were demonstrated as strong risk factors for increased overall morbidity. Sarcopenic obesity was associated with worse DFS and OS. This study underlines the role of nutrition and appropriate physical activity prior to therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Malnutrition and skeletal muscle waste (sarcopenia) are known as predictive factors for a poor postoperative outcome. Paradoxically, obesity seems to be associated with a survival advantage in wasting diseases such as cancer. Thus, the interpretation of body composition indices and their impact on rectal cancer therapy has become more and more complex. The aim of this study was to evaluate body composition indices in locally advanced rectal cancer patients prior to therapy and their impact on short- and long-term outcomes.
METHODS
METHODS
Between 2008 and 2018, 96 patients were included in this study. Pre-therapeutic CT scans were used to evaluate visceral and subcutaneous fat mass, as well as muscle mass. Body composition indices were compared to body mass index, morbidity, anastomotic leakage rate, local recurrency rate, and oncological long-term outcomes.
RESULTS
RESULTS
Increased visceral fat (
CONCLUSION
CONCLUSIONS
Muscle waste, older age, and comorbidities were demonstrated as strong risk factors for increased overall morbidity. Sarcopenic obesity was associated with worse DFS and OS. This study underlines the role of nutrition and appropriate physical activity prior to therapy.
Identifiants
pubmed: 37299595
pii: nu15112632
doi: 10.3390/nu15112632
pmc: PMC10255819
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Langenbecks Arch Surg. 2022 Nov;407(7):2945-2957
pubmed: 35849193
Front Oncol. 2022 Sep 29;12:994444
pubmed: 36249024
Br J Cancer. 2012 Sep 4;107(6):931-6
pubmed: 22871883
Langenbecks Arch Surg. 2022 May;407(3):1241-1249
pubmed: 35066629
JAMA Netw Open. 2021 Aug 2;4(8):e2115274
pubmed: 34459908
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Int J Colorectal Dis. 2022 Aug;37(8):1893-1900
pubmed: 35902393
Int J Colorectal Dis. 2012 Apr;27(4):497-505
pubmed: 22065107
Ann Surg Oncol. 2015 Aug;22(8):2663-8
pubmed: 25564158
Cancers (Basel). 2022 Mar 29;14(7):
pubmed: 35406504
Clin Nutr. 2023 May;42(5):687-699
pubmed: 36947988
World J Surg Oncol. 2022 Feb 25;20(1):51
pubmed: 35216606
JAMA Surg. 2021 Dec 1;156(12):1151-1158
pubmed: 34613330
Curr Opin Clin Nutr Metab Care. 2007 Jul;10(4):433-42
pubmed: 17563461
BJS Open. 2021 Sep 6;5(5):
pubmed: 34672343
Ann Coloproctol. 2020 Jan 16;:
pubmed: 32054253
Cancer Res Treat. 2020 Apr;52(2):563-572
pubmed: 31801316
Am Surg. 2010 Jul;76(7):747-51
pubmed: 20698384
Prz Gastroenterol. 2019;14(2):89-103
pubmed: 31616522
Oncology. 2011;81(5-6):395-402
pubmed: 22269999
Tech Coloproctol. 2023 May;27(5):407-418
pubmed: 36326939
Ann Surg. 2016 Feb;263(2):320-5
pubmed: 25643288
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Nutrition. 2020 Jul - Aug;75-76:110779
pubmed: 32268263
Int J Colorectal Dis. 2016 Apr;31(4):825-32
pubmed: 26861707
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Eur J Surg Oncol. 2019 Aug;45(8):1301-1309
pubmed: 30738589
Ann Surg Oncol. 2015 Oct;22(11):3625-31
pubmed: 25672564
Lancet. 1986 Nov 1;2(8514):996-9
pubmed: 2430152
Eur J Clin Nutr. 2018 Feb;72(2):288-296
pubmed: 29242526
Br J Cancer. 2011 Apr 12;104(8):1288-95
pubmed: 21448173
Chirurg. 2015 Nov;86(11):1072-82
pubmed: 26428227
Int J Colorectal Dis. 2020 Jul;35(7):1243-1253
pubmed: 32314189
J Am Geriatr Soc. 2002 May;50(5):897-904
pubmed: 12028178
JAMA Oncol. 2017 Dec 1;3(12):e172319
pubmed: 28796857